Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines

Journal of Cellular Biochemistry

Volumn 104, Issue 4, 2008, Pages 1356-1363

  Karagiannis, Emmanouil D ^a,b   Popel, Aleksander S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University School of Medicine   (United States)

Author keywords

Angiogenesis; Chemokinostatin; Endogenous; Endothelial cell; Inhibitor

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINOSTATIN 1; CHEMOKINOSTATIN 3; CHEMOKINOSTATIN 5; CHEMOKINOSTATIN 6; CHEMOKINOSTATIN 7; CHEMOKINOSTATIN 8; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOINFORMATICS; CELL MIGRATION; CELL PROLIFERATION; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SYNTHESIS;

AMINO ACID MOTIFS; ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES, CXC; ENDOTHELIAL CELLS; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; UMBILICAL VEINS;

EID: 46949106434     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21712     Document Type: Article

References (22)

1. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. 2000. CXC chemokines in angiogenesis. J Leukoc Biol 68:1-8.
2. Bikfalvi A. 2004. Platelet factor 4: An inhibitor of angiogenesis. Semin Thromb Hemost 30:379-385.
3. Bikfalvi A, Gimenez-Gallego G. 2004. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 30:137-144.
4. Cao Y, Chen C, Weatherbee JA, Tsang M, Folkman J. 1995. gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 182:2069-2077.
5. Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, Kisker O. 2005. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-11050.
6. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. 2004. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 173:6234-6240.
7. Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G, Kiss R. 2000. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Methods 43:15-24.
8. Folkman J. 1996. Endogenous inhibitors of angiogenesis. Harvey Lect 92:65-82.
9. Folkman J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18.
10. Folkman J. 2004. Endogenous angiogenesis inhibitors. Apmis 112:496-507.
11. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. 1996. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518-1520.
12. Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A. 1999. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 94:984-993.
13. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537-1549.
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
15. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. 2004. CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 25:201-209.
16. Strieter RM, Belperio JA, Phillips RJ, Keane MP. 2004. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14:195-200.
17. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. 2005. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16:593-609.
18. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. 2006. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768-778.
19. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. 2005. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65:3656-3663.
20. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511.
21. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ. 2004. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96:1473-1477.
22. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. 1999. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112:531-552.